- All
- Product Name
- Product Keyword
- Product Model
- Product Summary
- Product Description
- Multi Field Search
Views: 71 Author: Unibest Industrial Publish Time: 2024-11-18 Origin: Site
Report generated for the week of 2024-11-18 by Unibest Digital Center. Current analysis scope only include the US FDA.
This week, there are 8 drugs in the patent and exclusivity list. They are:
- KALEO INC's AUVI-Q, containing active ingredient EPINEPHRINE
- NOVO NORDISK INC's VICTOZA, containing active ingredient LIRAGLUTIDE
- NOVO NORDISK INC's SAXENDA, containing active ingredient LIRAGLUTIDE
- BRISTOL MYERS SQUIBB's REVLIMID, containing active ingredient LENALIDOMIDE
- CUMBERLAND PHARMACEUTICALS INC's CALDOLOR, containing active ingredient IBUPROFEN
- AMERICAN REGENT INC's INJECTAFER, containing active ingredient FERRIC CARBOXYMALTOSE
- ALNYLAM PHARMACEUTICALS INC's GIVLAARI, containing active ingredient GIVOSIRAN SODIUM
- AADI BIOSCIENCE INC's FYARRO, containing active ingredient SIROLIMUS
From KALEO INC; for treating life-threatening allergic reactions.
Approved in Aug 10, 2012, used as Reference Listed Drug and Reference Standard
There are 10 future patent(s) for this application. The earliest expires on 2025-04-30, and the latest expires on 2037-12-21.
| Patent No | Patent Use Code | Patent Use Definition | Patent Expiration Date |
|---|---|---|---|
| 8425462 | NaN | NaN | 2024-11-23 |
| 10737028 | NaN | NaN | 2024-11-23 |
| 8608698 | NaN | NaN | 2024-11-23 |
| 8361029 | NaN | NaN | 2024-11-23 |
| 9737669 | NaN | NaN | 2024-11-23 |
| 10314977 | NaN | NaN | 2024-11-23 |
| 8313466 | NaN | NaN | 2024-11-23 |
Approved in Nov 17, 2017, used as Reference Listed Drug
There are 10 future patent(s) for this application. The earliest expires on 2025-04-30, and the latest expires on 2037-12-21.
| Patent No | Patent Use Code | Patent Use Definition | Patent Expiration Date |
|---|---|---|---|
| 10314977 | NaN | NaN | 2024-11-23 |
| 10737028 | NaN | NaN | 2024-11-23 |
| 8608698 | NaN | NaN | 2024-11-23 |
| 8425462 | NaN | NaN | 2024-11-23 |
| 8361029 | NaN | NaN | 2024-11-23 |
| 8313466 | NaN | NaN | 2024-11-23 |
| 9833573 | U-2172 | METHOD TO TREAT SEVERE ALLERGIC EMERGENCIES IN PATIENTS WEIGHING 7.5 TO 15 KG (16.5 TO 33 LBS) | 2024-11-23 |
| 9737669 | NaN | NaN | 2024-11-23 |
Approved in Aug 10, 2012, used as Reference Listed Drug
There are 10 future patent(s) for this application. The earliest expires on 2025-04-30, and the latest expires on 2037-12-21.
| Patent No | Patent Use Code | Patent Use Definition | Patent Expiration Date |
|---|---|---|---|
| 8425462 | NaN | NaN | 2024-11-23 |
| 10314977 | NaN | NaN | 2024-11-23 |
| 8608698 | NaN | NaN | 2024-11-23 |
| 8313466 | NaN | NaN | 2024-11-23 |
| 10737028 | NaN | NaN | 2024-11-23 |
| 9737669 | NaN | NaN | 2024-11-23 |
| 8361029 | NaN | NaN | 2024-11-23 |
From BRISTOL MYERS SQUIBB; for treating adults with multiple myeloma, mantle cell lymphoma, myelodysplastic syndromes, and follicular lymphoma & marginal zone lymphoma.
Approved in Dec 27, 2005, used as Reference Listed Drug
There are 2 future patent(s) for this application. The earliest expires on 2027-04-27, and the latest expires on 2028-03-08.
| Patent No | Patent Use Code | Patent Use Definition | Patent Expiration Date |
|---|---|---|---|
| 7855217 | NaN | NaN | 2024-11-24 |
Approved in Jun 29, 2006, used as Reference Listed Drug
There are 2 future patent(s) for this application. The earliest expires on 2027-04-27, and the latest expires on 2028-03-08.
| Patent No | Patent Use Code | Patent Use Definition | Patent Expiration Date |
|---|---|---|---|
| 7855217 | NaN | NaN | 2024-11-24 |
Approved in Dec 21, 2011, used as Reference Listed Drug
There are 2 future patent(s) for this application. The earliest expires on 2027-04-27, and the latest expires on 2028-03-08.
| Patent No | Patent Use Code | Patent Use Definition | Patent Expiration Date |
|---|---|---|---|
| 7855217 | NaN | NaN | 2024-11-24 |
Approved in Jun 5, 2013, used as Reference Listed Drug
There are 2 future patent(s) for this application. The earliest expires on 2027-04-27, and the latest expires on 2028-03-08.
| Patent No | Patent Use Code | Patent Use Definition | Patent Expiration Date |
|---|---|---|---|
| 7855217 | NaN | NaN | 2024-11-24 |
Approved in Jun 29, 2006, used as Reference Listed Drug and Reference Standard
There are 2 future patent(s) for this application. The earliest expires on 2027-04-27, and the latest expires on 2028-03-08.
| Patent No | Patent Use Code | Patent Use Definition | Patent Expiration Date |
|---|---|---|---|
| 7855217 | NaN | NaN | 2024-11-24 |
Approved in Dec 27, 2005, used as Reference Listed Drug
There are 2 future patent(s) for this application. The earliest expires on 2027-04-27, and the latest expires on 2028-03-08.
| Patent No | Patent Use Code | Patent Use Definition | Patent Expiration Date |
|---|---|---|---|
| 7855217 | NaN | NaN | 2024-11-24 |
From NOVO NORDISK INC; for weight loss.
Approved in Dec 23, 2014, used as Reference Listed Drug and Reference Standard
There are 31 future patent(s) for this application. The earliest expires on 2025-08-13, and the latest expires on 2037-07-09.
| Patent No | Patent Use Code | Patent Use Definition | Patent Expiration Date |
|---|---|---|---|
| 7762994*PED | NaN | NaN | 2024-11-23 |
From NOVO NORDISK INC; for type 2 diabetes.
Approved in Jan 25, 2010, used as Reference Listed Drug and Reference Standard
There are 6 future patent(s) for this application. The earliest expires on 2025-08-13, and the latest expires on 2037-07-09.
| Patent No | Patent Use Code | Patent Use Definition | Patent Expiration Date |
|---|---|---|---|
| 7762994*PED | NaN | NaN | 2024-11-23 |
From AMERICAN REGENT INC; for treating iron deficiency anemia.
Approved in Apr 28, 2021, used as Reference Listed Drug and Reference Standard
There are 1 future exclusivity(ies) for this drug product. The earliest expires on 2026-05-31, and the latest expires on 2026-05-31.
| Exclusivity Date | Exclusivity Use Definition |
|---|---|
| 2024-11-19 | NEW PATIENT POPULATION |
Approved in Oct 8, 2020, used as Reference Listed Drug and Reference Standard
There are 1 future exclusivity(ies) for this drug product. The earliest expires on 2026-05-31, and the latest expires on 2026-05-31.
| Exclusivity Date | Exclusivity Use Definition |
|---|---|
| 2024-11-19 | NEW PATIENT POPULATION |
Approved in Jul 25, 2013, used as Reference Listed Drug and Reference Standard
There are 1 future exclusivity(ies) for this drug product. The earliest expires on 2026-05-31, and the latest expires on 2026-05-31.
| Exclusivity Date | Exclusivity Use Definition |
|---|---|
| 2024-11-19 | NEW PATIENT POPULATION |
From ALNYLAM PHARMACEUTICALS INC; for treating acute hepatic porphyria.
Approved in Nov 20, 2019, used as Reference Listed Drug and Reference Standard
There are 1 future exclusivity(ies) for this drug product. The earliest expires on 2026-11-20, and the latest expires on 2026-11-20.
| Exclusivity Date | Exclusivity Use Definition |
|---|---|
| 2024-11-20 | NEW CHEMICAL ENTITY |
From CUMBERLAND PHARMACEUTICALS INC; for treating both fever and mild to severe pain.
Approved in Jan 25, 2019, used as Reference Listed Drug and Reference Standard
There are 1 future exclusivity(ies) for this drug product. The earliest expires on 2026-05-11, and the latest expires on 2026-05-11.
| Exclusivity Date | Exclusivity Use Definition |
|---|---|
| 2024-11-19 | NaN |
Approved in Jun 11, 2009, used as Reference Listed Drug and Reference Standard
There are 1 future exclusivity(ies) for this drug product. The earliest expires on 2026-05-11, and the latest expires on 2026-05-11.
| Exclusivity Date | Exclusivity Use Definition |
|---|---|
| 2024-11-19 | NaN |
From AADI BIOSCIENCE INC; for treating adults with malignant perivascular epithelioid cell tumors.
Approved in Nov 22, 2021, used as Reference Listed Drug and Reference Standard
There are 1 future exclusivity(ies) for this drug product. The earliest expires on 2028-11-22, and the latest expires on 2028-11-22.
| Exclusivity Date | Exclusivity Use Definition |
|---|---|
| 2024-11-22 | NEW PRODUCT |
